Clinical Research Directory

Inclusion Criteria: * Capable of providing informed consent and willing to adhere to all protocol requirements * patients aged \> or equal to 40 years * Histologically confirmed melanoma of any stage planned for, commenced, or completed treatment with ICI * having acceptable imaging quality deemed by the core laboratory * Investigator believes that the participant is willing to adhere to all protocol requirements, including returning for follow up CTCA. Exclusion Criteria: * Known clinically manifest cardiovascular disease * Female participants must not be pregnant, breastfeeding or plan to become pregnant during the study. * Estimated glomerular filtration rate of \<45 mL/min calculated using the Chronic Kidney Disease Epidemiology Collaboration equation * Severe liver disease or cirrhosis * History of any other malignancy within the past 5 years in addition to melanoma with the exception of non-melanoma skin cancers * Prognostic factors associated with an expected survival less than 18 months at Investigators' discretion (e.g. unresectable brain metastases) * Evidence of any other clinically significant non-cardiac disease or condition that, in the opinion of the Investigator, would preclude participation in the study * Major allergy to iodine * Participation in another clinical trial that does not allow participation in multiple trials at the same time